TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Brief Summary: The purpose of this study is to evaluate the efficacy of guselkumab compared with secukinumab for the treatment of participants with moderate to severe plaque-type psoriasis.


Options:
A: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab | Arm Label: ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, Placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Adalimumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo for risankizumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Biological: placebo for adalimumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: BIOLOGICAL; Name: placebo for adalimumab; Assigned to Arm(s): Risankizumab (Part A)
C: Arm Label: Group I: Guselkumab Plus Placebo; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Arm Label: Group II: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Group I: Guselkumab Plus Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I: Guselkumab Plus Placebo | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Group II: Secukinumab
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 150mg | Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 150mg; Assigned to Arm(s): Secukinumab 150 mg | Intervention Type: DRUG; Name: Secukinumab 300mg; Assigned to Arm(s): Secukinumab 300 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Brief Summary: The purpose of this study is to evaluate the efficacy of guselkumab compared with secukinumab for the treatment of participants with moderate to severe plaque-type psoriasis.


Options:
A: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: placebo for ustekinumab | Arm Label: Ustekinumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab, Drug: placebo for risankizumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for ustekinumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for ustekinumab; Assigned to Arm(s): Placebo (Part A), Risankizumab (Part A)
B: Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab 45/90 mg, Drug: placebo secukinumab | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg | Intervention Type: DRUG; Name: ustekinumab 45/90 mg; Assigned to Arm(s): Ustekinumab | Intervention Type: DRUG; Name: placebo secukinumab; Assigned to Arm(s): Ustekinumab
C: Arm Label: KHK4827 70mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 140mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: KHK4827 210mg SC; Type: EXPERIMENTAL; Interventions: Drug: KHK4827 | Arm Label: Placebo SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: KHK4827; Assigned to Arm(s): KHK4827 140mg SC, KHK4827 210mg SC, KHK4827 70mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo SC
D: Arm Label: Group I: Guselkumab Plus Placebo; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Arm Label: Group II: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Group I: Guselkumab Plus Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I: Guselkumab Plus Placebo | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Group II: Secukinumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Contact Phase Activation During Hemodialysis Using Different Dialysis Membranes: a Prospective Randomized Crossover Study
Brief Summary: Every patient included in the study will undergo 3 standardised hemodialysis treatments, each using a different dialysis membrane (PMMA, PS, AN69ST). The order of the membranes used will be randomized.

During each conventional and standardised hemodialysis treatment, 6 blood samples will be taken at different time points (T0, T5, T15, T30, T90, T240) to evaluate coagulation activation (TAT, PF1+2, d-dimers, TF) and, more specifically, activation of the contact phase pathway of coagulation (kallikrein, fXIa, fXIIa).


Options:
A: Arm Label: Heparin free dialysis standard of care; Type: ACTIVE_COMPARATOR; Interventions: Other: Heparin free dialysis technique | Arm Label: Heparin free dialysis with Evodial; Type: EXPERIMENTAL; Interventions: Device: Evodial | Intervention Type: OTHER; Name: Heparin free dialysis technique; Assigned to Arm(s): Heparin free dialysis standard of care | Intervention Type: DEVICE; Name: Evodial; Assigned to Arm(s): Heparin free dialysis with Evodial
B: Arm Label: "EvoCit"; Type: ACTIVE_COMPARATOR; Interventions: Device: EvoCit | Arm Label: "EvoHep"; Type: ACTIVE_COMPARATOR; Interventions: Device: EvoHep | Intervention Type: DEVICE; Name: EvoCit; Assigned to Arm(s): "EvoCit" | Intervention Type: DEVICE; Name: EvoHep; Assigned to Arm(s): "EvoHep"
C: Arm Label: apixaban; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Arm Label: warfarin; Type: EXPERIMENTAL; Interventions: Drug: warfarin | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): warfarin
D: Arm Label: PMMA (BKU); Type: ACTIVE_COMPARATOR; Interventions: Device: PMMA (BKU) | Arm Label: PS (Phylter); Type: ACTIVE_COMPARATOR; Interventions: Device: PS (Phylter) | Arm Label: AN69ST (Evodial); Type: ACTIVE_COMPARATOR; Interventions: Device: AN69ST (Evodial) | Intervention Type: DEVICE; Name: PMMA (BKU); Assigned to Arm(s): PMMA (BKU) | Intervention Type: DEVICE; Name: PS (Phylter); Assigned to Arm(s): PS (Phylter) | Intervention Type: DEVICE; Name: AN69ST (Evodial); Assigned to Arm(s): AN69ST (Evodial)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Brief Summary: This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is effective in treating patients with MET-driven PRCC, how it compares with another medication frequently used to treat this disease called sunitinib, and what side effects it might cause.


Options:
A: Arm Label: AGS-003 + Standard Treatment; Type: EXPERIMENTAL; Interventions: Biological: AGS-003 | Arm Label: Standard Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Treatment | Intervention Type: DRUG; Name: Standard Treatment; Assigned to Arm(s): Standard Treatment | Intervention Type: BIOLOGICAL; Name: AGS-003; Assigned to Arm(s): AGS-003 + Standard Treatment
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Temsirolimus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon-Alfa 9MU | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Interferon-Alfa 9MU; Assigned to Arm(s): 2
C: Arm Label: Savolitinib; Type: EXPERIMENTAL; Interventions: Drug: Savolitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Savolitinib; Assigned to Arm(s): Savolitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy
Brief Summary: The purpose of this study is to show non-inferiority between two medications used for medical treatment of withdrawal seen in Neonatal Abstinence Syndrome (NAS), Clonidine and Morphine Sulfate (used in routine care) on length of treatment for NAS .


Options:
A: Arm Label: Stochastic Vibrotactile Stimulation (SVS); Type: EXPERIMENTAL; Interventions: Device: Stochastic Vibrotactile Stimulation (SVS) | Arm Label: Treatment as Usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Stochastic Vibrotactile Stimulation (SVS); Assigned to Arm(s): Stochastic Vibrotactile Stimulation (SVS)
B: Arm Label: Clonidine treatment; Type: EXPERIMENTAL; Interventions: Drug: Clonidine HCL | Intervention Type: DRUG; Name: Clonidine HCL; Assigned to Arm(s): Clonidine treatment
C: Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine
D: Arm Label: Clonidine; Type: EXPERIMENTAL; Interventions: Drug: Clonidine | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine Sulfate | Intervention Type: DRUG; Name: Clonidine; Assigned to Arm(s): Clonidine | Intervention Type: DRUG; Name: Morphine Sulfate; Assigned to Arm(s): Morphine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Stepped Care for Suicide Prevention in Teens and Young Adults
Brief Summary: This randomized controlled trial will evaluate two approaches to achieving the aspirational goal of Zero Suicide within a health system: 1) Zero Suicide Best Practices initiated through a zero suicide quality improvement initiative within a health system; and 2) Zero Suicide Best Practices plus an innovative stepped care for suicide prevention intervention for adolescents and young adults that matches treatment intensity with risk levels for suicide/self-harm. ..


Options:
A: Arm Label: Peer Mentorship intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer mentorship | Arm Label: Enhanced Usual Care (EUC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: Peer mentorship; Assigned to Arm(s): Peer Mentorship intervention | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care (EUC)
B: Arm Label: Post Admission Cognitive Therapy (PACT); Type: EXPERIMENTAL; Interventions: Behavioral: Post Admission Cognitive Therapy (PACT) | Arm Label: Enhanced Usual Care (EUC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Post Admission Cognitive Therapy (PACT); Assigned to Arm(s): Post Admission Cognitive Therapy (PACT)
C: Arm Label: Zero Suicide Quality Improvement (ZSQI); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Zero Suicide Quality Improvement | Arm Label: Stepped Care for Suicide Prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Stepped Care for Suicide Prevention, Behavioral: Zero Suicide Quality Improvement | Intervention Type: BEHAVIORAL; Name: Stepped Care for Suicide Prevention; Assigned to Arm(s): Stepped Care for Suicide Prevention | Intervention Type: BEHAVIORAL; Name: Zero Suicide Quality Improvement; Assigned to Arm(s): Stepped Care for Suicide Prevention, Zero Suicide Quality Improvement (ZSQI)
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Quetiapine fumarate | Intervention Type: DRUG; Name: Quetiapine fumarate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Stepped Care for Suicide Prevention in Teens and Young Adults
Brief Summary: This randomized controlled trial will evaluate two approaches to achieving the aspirational goal of Zero Suicide within a health system: 1) Zero Suicide Best Practices initiated through a zero suicide quality improvement initiative within a health system; and 2) Zero Suicide Best Practices plus an innovative stepped care for suicide prevention intervention for adolescents and young adults that matches treatment intensity with risk levels for suicide/self-harm. ..


Options:
A: Arm Label: Mindfulness skills; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness skills training | Arm Label: Interpersonal effectiveness skills; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interpersonal Effectiveness skills training | Intervention Type: BEHAVIORAL; Name: Mindfulness skills training; Assigned to Arm(s): Mindfulness skills | Intervention Type: BEHAVIORAL; Name: Interpersonal Effectiveness skills training; Assigned to Arm(s): Interpersonal effectiveness skills
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 24 hour phone line | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment as usual | Intervention Type: OTHER; Name: 24 hour phone line; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: treatment as usual; Assigned to Arm(s): 2
C: Arm Label: Dialectical Behaviour Therapy-6 months; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy-6 months | Arm Label: Dialectical Behaviour Therapy-12 months; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dialectical Behaviour Therapy-12 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-6 months; Assigned to Arm(s): Dialectical Behaviour Therapy-6 months | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy-12 months; Assigned to Arm(s): Dialectical Behaviour Therapy-12 months
D: Arm Label: Zero Suicide Quality Improvement (ZSQI); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Zero Suicide Quality Improvement | Arm Label: Stepped Care for Suicide Prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Stepped Care for Suicide Prevention, Behavioral: Zero Suicide Quality Improvement | Intervention Type: BEHAVIORAL; Name: Stepped Care for Suicide Prevention; Assigned to Arm(s): Stepped Care for Suicide Prevention | Intervention Type: BEHAVIORAL; Name: Zero Suicide Quality Improvement; Assigned to Arm(s): Stepped Care for Suicide Prevention, Zero Suicide Quality Improvement (ZSQI)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Stepped Care for Suicide Prevention in Teens and Young Adults
Brief Summary: This randomized controlled trial will evaluate two approaches to achieving the aspirational goal of Zero Suicide within a health system: 1) Zero Suicide Best Practices initiated through a zero suicide quality improvement initiative within a health system; and 2) Zero Suicide Best Practices plus an innovative stepped care for suicide prevention intervention for adolescents and young adults that matches treatment intensity with risk levels for suicide/self-harm. ..


Options:
A: Intervention Type: BEHAVIORAL; Name: Problem-Solving Skills Training; Assigned to Arm(s): N/A
B: Arm Label: Mindfulness; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness | Arm Label: Interpersonal effectiveness; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: interpersonal effectiveness | Intervention Type: BEHAVIORAL; Name: Mindfulness; Assigned to Arm(s): Mindfulness | Intervention Type: BEHAVIORAL; Name: interpersonal effectiveness; Assigned to Arm(s): Interpersonal effectiveness
C: Arm Label: Zero Suicide Quality Improvement (ZSQI); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Zero Suicide Quality Improvement | Arm Label: Stepped Care for Suicide Prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Stepped Care for Suicide Prevention, Behavioral: Zero Suicide Quality Improvement | Intervention Type: BEHAVIORAL; Name: Stepped Care for Suicide Prevention; Assigned to Arm(s): Stepped Care for Suicide Prevention | Intervention Type: BEHAVIORAL; Name: Zero Suicide Quality Improvement; Assigned to Arm(s): Stepped Care for Suicide Prevention, Zero Suicide Quality Improvement (ZSQI)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 24 hour phone line | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment as usual | Intervention Type: OTHER; Name: 24 hour phone line; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: treatment as usual; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Stepped Care for Suicide Prevention in Teens and Young Adults
Brief Summary: This randomized controlled trial will evaluate two approaches to achieving the aspirational goal of Zero Suicide within a health system: 1) Zero Suicide Best Practices initiated through a zero suicide quality improvement initiative within a health system; and 2) Zero Suicide Best Practices plus an innovative stepped care for suicide prevention intervention for adolescents and young adults that matches treatment intensity with risk levels for suicide/self-harm. ..


Options:
A: Arm Label: Zero Suicide Quality Improvement (ZSQI); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Zero Suicide Quality Improvement | Arm Label: Stepped Care for Suicide Prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Stepped Care for Suicide Prevention, Behavioral: Zero Suicide Quality Improvement | Intervention Type: BEHAVIORAL; Name: Stepped Care for Suicide Prevention; Assigned to Arm(s): Stepped Care for Suicide Prevention | Intervention Type: BEHAVIORAL; Name: Zero Suicide Quality Improvement; Assigned to Arm(s): Stepped Care for Suicide Prevention, Zero Suicide Quality Improvement (ZSQI)
B: Arm Label: Brief Admission; Type: EXPERIMENTAL; Interventions: Other: Brief Admission | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Brief Admission; Assigned to Arm(s): Brief Admission
C: Arm Label: Intensive Group Analytic Psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Group Analytic Psychotherapy | Arm Label: Intensive GCBT; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive transdiagnostic cognitive-behavioral group therapy | Arm Label: Wait-list control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive Group Analytic Psychotherapy; Assigned to Arm(s): Intensive Group Analytic Psychotherapy | Intervention Type: BEHAVIORAL; Name: Intensive transdiagnostic cognitive-behavioral group therapy; Assigned to Arm(s): Intensive GCBT
D: Arm Label: Combined psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Combined psychotherapy | Arm Label: Outpatient individual psychotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Outpatient individual psychotherapy | Intervention Type: BEHAVIORAL; Name: Combined psychotherapy; Assigned to Arm(s): Combined psychotherapy | Intervention Type: BEHAVIORAL; Name: Outpatient individual psychotherapy; Assigned to Arm(s): Outpatient individual psychotherapy

Answer: A